The Ethics of Access
The deep inequalities in who can access psychedelic medicines - economic barriers to clinical therapy, racial disparities in research, and indigenous communities' complex relationship to the commercialization of their traditions.
Access to psychedelic medicines - whether in clinical, ceremonial, or informal contexts - is currently highly unequal across dimensions of wealth, race, geography, and cultural background. The emerging field of psychedelic-assisted therapy, in particular, carries significant access concerns as it moves toward commercialization. Understanding these concerns is relevant both to the ethical dimensions of the field and to the practical realities facing people who would benefit from these medicines.
Economic access is the most visible barrier. Clinical psychedelic therapy sessions typically involve multiple preparatory appointments, a supervised medicine session of several hours (requiring at least one and often two trained practitioners), and several integration sessions afterward. This staffing-intensive model is expensive, and it is not yet covered by most insurance. Current estimates place the cost of a full MDMA-assisted therapy protocol for PTSD in the range of ten to fifteen thousand dollars. Psilocybin-assisted therapy protocols are likely to be similarly priced.
Racial and cultural access involves different dynamics. The research base for these therapies has been conducted primarily with white, highly educated, economically privileged populations - not because people of color are less interested, but because the recruitment and screening processes have not been designed to include them, and because historical trauma from medical institutions and drug law enforcement creates understandable barriers to participation. The therapeutic models that have been developed reflect the cultural frameworks and communication styles of dominant Western culture in ways that may not translate well across cultural contexts.
Indigenous communities face a distinct access question: the medicalization and commercialization of substances central to their cultural and spiritual life proceeds largely without their participation in governance, their benefit from commercial value, or adequate acknowledgment of the knowledge systems that made these medicines accessible to Western science in the first place.
The ethics of access question is ultimately one about who is imagined as the intended beneficiary of these medicines and who, structurally, ends up being able to reach them.